Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

The study included 1,028 participants (mean age at baseline 76.4 years; 47.6% female): 521 with ADP, 96 with LBP, and 411 with mixed AD-LBP. A three-cluster clinical subtype (CS) solution best fit the data. The most symptomatic group (CS-3) had the youngest age at first visit (mean 72.1 years), the highest BPSD burden, and the fastest cognitive and functional decline across ADP and AD-LBP groups. CS-1 and CS-2 exhibited milder early cognitive impairment and lower BPSD burden. Within ADP and AD-LBP, CS-2 showed slower progression than CS-1, fewer APOE ε4 carriers (41% vs. 58%), and better memory scores, despite reporting a higher frequency of agitation. These findings reveal distinct clinical subtypes that cut across traditional pathological boundaries, emphasizing the need to incorporate both cognitive and behavioral features into early dementia characterization. This multidimensional approach can improve guide personalized prognosis and care planning and enhance clinical trial design by considering disease heterogeneity. The study supports integrated clinical profiling as important factor in robust evaluation of dementia outcomes.

Key findings

Why it matters

This study found distinct clinical subtypes of dementia that cut across traditional pathological boundaries, based on cognitive and behavioral features. It suggests that incorporating both cognitive and behavioral features into early dementia characterization can improve personalized prognosis and care planning and enhance clinical trial design.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 3 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 55 of 100.55 of 100 points earned45 not earned

Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neurology Open Access)
Journal's citation record 0 / 4 Neurology Open Access: journal h-index 5 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 3 / 4 1,028 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 3 / 6 Cited 4.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Jagan A. Pillai: h-index 22 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41809433)
Free to read 2 / 2 Free to read
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Wang, M., Wu, H., Bonner‐Jackson, A., Chen, Y., Tang, W., Feng, H., et al. (2026). Early Behavioral and Cognitive Changes in Patients With Pathologically Confirmed Alzheimer Disease, Lewy Body Dementia, and Mixed Dementia. Neurology Open Access. https://doi.org/10.1212/wn9.0000000000000055

Vancouver

Wang M, Wu H, Bonner‐Jackson A, Chen Y, Tang W, Feng H, et al. Early Behavioral and Cognitive Changes in Patients With Pathologically Confirmed Alzheimer Disease, Lewy Body Dementia, and Mixed Dementia. Neurology Open Access. 2026. doi:10.1212/wn9.0000000000000055. PMID: 41809433.

BibTeX

@article{wang2026-41809433,
  author  = {Wang, Ming and Wu, Hongke and Bonner‐Jackson, Aaron and Chen, Yiming and Tang, Wen and Feng, Hao and Zhang, Lijun and Chen, Chixiang and others},
  title   = {{Early Behavioral and Cognitive Changes in Patients With Pathologically Confirmed Alzheimer Disease, Lewy Body Dementia, and Mixed Dementia}},
  journal = {Neurology Open Access},
  year    = {2026},
  doi     = {10.1212/wn9.0000000000000055},
  pmid    = {41809433},
  url     = {https://doi.org/10.1212/wn9.0000000000000055}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Related studies in Genetics

Similar studies

More on Genetics

See all studies in Genetics →